Medtronic Inc

MDT-N

NYSE:MDT

111.72
0.68 (0.61%)

Analysis and Opinions about MDT-N

Signal
Opinion
Expert
BUY
BUY
October 17, 2019
Good company. Biggest product is pacemakers. Trades at 19x earnings. Good stock price stability. Trades attractively against peers. Given the multiple, and predictability of earnings, you should look at a 10% return or greater over time.
Medtronic Inc (MDT-N)
October 17, 2019
Good company. Biggest product is pacemakers. Trades at 19x earnings. Good stock price stability. Trades attractively against peers. Given the multiple, and predictability of earnings, you should look at a 10% return or greater over time.
Gordon Reid
President, GoodReid Investment Counsel
Price
$108.740
Owned
No
TOP PICK
TOP PICK
October 2, 2019
They built the first pacemaker and have gone on to make several similar devices. They have gone global. Places like India need these devices for heart disease, for example. The CEO is from Bangladesh and understands this vast market. They are moving from selling the device to improving people's health. If they succeed, they will be hugely profitable. (Analysts’ price target is $116.38)
Medtronic Inc (MDT-N)
October 2, 2019
They built the first pacemaker and have gone on to make several similar devices. They have gone global. Places like India need these devices for heart disease, for example. The CEO is from Bangladesh and understands this vast market. They are moving from selling the device to improving people's health. If they succeed, they will be hugely profitable. (Analysts’ price target is $116.38)
Michael Decter
President & CEO, Lawrence Decter Investment Counsel
Price
$105.940
Owned
Yes
BUY
BUY
September 6, 2019
The stock couldn’t look any better. An absolute buy and hold. It took a long time to break through $100 but they’ve done it. Would be a buyer here.
Medtronic Inc (MDT-N)
September 6, 2019
The stock couldn’t look any better. An absolute buy and hold. It took a long time to break through $100 but they’ve done it. Would be a buyer here.
Elliott Fishman
Director of U.S. and international equity trading, Trading Services Group, Scotia Wealth
Price
$108.690
Owned
No
HOLD
HOLD
May 3, 2019
Don't sell it just to go into a Merck. Add to your diversity instead by buying a basket. Likes Medtronic. Diversified. Into robotic surgery. 8% EPS growth. Relatively inexpensive. Very large, so you don't get the same growth as smaller companies.
Don't sell it just to go into a Merck. Add to your diversity instead by buying a basket. Likes Medtronic. Diversified. Into robotic surgery. 8% EPS growth. Relatively inexpensive. Very large, so you don't get the same growth as smaller companies.
Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$89.580
Owned
Unknown
BUY
BUY
December 3, 2018
Likes it very much. Thought bought Covidien, a medical device maker, a few years back. They're executing very well, such as their diabetes franchise which boosted their guidance recently to 5.5% growth in 2019. Valuation good at 17.5x vs. peers. Many of their products are essential services which is anothe tailwind.
Medtronic Inc (MDT-N)
December 3, 2018
Likes it very much. Thought bought Covidien, a medical device maker, a few years back. They're executing very well, such as their diabetes franchise which boosted their guidance recently to 5.5% growth in 2019. Valuation good at 17.5x vs. peers. Many of their products are essential services which is anothe tailwind.
Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$98.750
Owned
Yes
PAST TOP PICK
PAST TOP PICK
September 18, 2018

(A Top Pick November 13, 2017. Up 24%). He owned this as a diversified play on the medical device market. He sold the stock when it reached $90 and used the proceeds to buy Boston Scientific instead.

Medtronic Inc (MDT-N)
September 18, 2018

(A Top Pick November 13, 2017. Up 24%). He owned this as a diversified play on the medical device market. He sold the stock when it reached $90 and used the proceeds to buy Boston Scientific instead.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$96.880
Owned
Yes
WEAK BUY
WEAK BUY
May 9, 2018

He likes medical device manufacturers. It seems they are taking market share in a booming market. They are well diversified. The company continues to put up great numbers.

He likes medical device manufacturers. It seems they are taking market share in a booming market. They are well diversified. The company continues to put up great numbers.

Cameron Hurst
Chief Investment Officer, Equium Capital Management
Price
$84.060
Owned
No
BUY
BUY
March 21, 2018

Likes this. One of the most dominant medtech companies, diversified from hips and knees to cardio. Good 15x forward earnings and a stable dividend yield. It's an economy of scale game in medtech, and MDT is well-positioned. Great
balance sheet and growth profile.

Medtronic Inc (MDT-N)
March 21, 2018

Likes this. One of the most dominant medtech companies, diversified from hips and knees to cardio. Good 15x forward earnings and a stable dividend yield. It's an economy of scale game in medtech, and MDT is well-positioned. Great
balance sheet and growth profile.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$80.040
Owned
Unknown
COMMENT
COMMENT
January 31, 2018

A dividend aristocrat, gradually increasing the dividend every year. They are in medical devices. Any increase in surgery, hospital time and heart disease would be an upside for this story. It’s been a relative laggard for the group, but has been a very good performer longer-term, and has rewarded shareholders very well. Sees this as a mutual fund of device companies.

Medtronic Inc (MDT-N)
January 31, 2018

A dividend aristocrat, gradually increasing the dividend every year. They are in medical devices. Any increase in surgery, hospital time and heart disease would be an upside for this story. It’s been a relative laggard for the group, but has been a very good performer longer-term, and has rewarded shareholders very well. Sees this as a mutual fund of device companies.

Darren Sissons
Vice President and Partner, Campbell Lee & Ross
Price
$85.890
Owned
Yes
HOLD
HOLD
January 11, 2018

Medical devices. A good global name. He has been bullish on medical devices for quite some time. He has shifted that down recently because it was getting close to his break points. Earnings were ratcheted down because of hurricane noise because of Puerto Rican noise. IHI-N is the US ETF he would use to take positions in this sector. You want to get through this next quarter. You have good metrics.

Medtronic Inc (MDT-N)
January 11, 2018

Medical devices. A good global name. He has been bullish on medical devices for quite some time. He has shifted that down recently because it was getting close to his break points. Earnings were ratcheted down because of hurricane noise because of Puerto Rican noise. IHI-N is the US ETF he would use to take positions in this sector. You want to get through this next quarter. You have good metrics.

Cameron Hurst
Chief Investment Officer, Equium Capital Management
Price
$85.730
Owned
Unknown
TOP PICK
TOP PICK
November 13, 2017

This does stuff mainly related to cardiovascular, diabetes, spinal implants and a lot of neurology stuff. The stock has been bouncing between $90 and $75. Has 4%-5% earnings growth. Dividend yield of 2.3%. (Analysts’ price target is $90.)

Medtronic Inc (MDT-N)
November 13, 2017

This does stuff mainly related to cardiovascular, diabetes, spinal implants and a lot of neurology stuff. The stock has been bouncing between $90 and $75. Has 4%-5% earnings growth. Dividend yield of 2.3%. (Analysts’ price target is $90.)

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$79.200
Owned
Yes
COMMENT
COMMENT
October 13, 2017

This has certainly had its good days. It’s been quite a good company for many years. He likes the medical technology space.

Medtronic Inc (MDT-N)
October 13, 2017

This has certainly had its good days. It’s been quite a good company for many years. He likes the medical technology space.

Matt Kacur
President, FSA Financial Science and Art
Price
$78.070
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
May 23, 2017

(A Top Pick May 25/16. Up 7%.) He really likes the medical device space. If he were to buy something today, he would probably buy a Stryker (SYK-N). The nice thing about devices is that it is not completely dependent on insurance pays. If you would like the whole sector, you can buy the ETF IHI-N.

(A Top Pick May 25/16. Up 7%.) He really likes the medical device space. If he were to buy something today, he would probably buy a Stryker (SYK-N). The nice thing about devices is that it is not completely dependent on insurance pays. If you would like the whole sector, you can buy the ETF IHI-N.

David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$84.610
Owned
No
WEAK BUY
WEAK BUY
April 24, 2017

They have struggled over the most recent years after being a darling. There is the question of how healthcare will be paid for in the US. Device companies have the hardest headwinds. They are also in a very competitive area. It is not expensive and is a perfectly good way to be in the health care area. Their struggles may mean they have more upside potential if the healthcare sector improves.

Medtronic Inc (MDT-N)
April 24, 2017

They have struggled over the most recent years after being a darling. There is the question of how healthcare will be paid for in the US. Device companies have the hardest headwinds. They are also in a very competitive area. It is not expensive and is a perfectly good way to be in the health care area. Their struggles may mean they have more upside potential if the healthcare sector improves.

Liz Miller
President, Summit Place Financial Advisors
Price
$80.650
Owned
Unknown
PAST TOP PICK
PAST TOP PICK
April 19, 2017

(A Top Pick May 13/16. Up 2%.) The leading medical device company. He owns it because they have a plethora of products right across the range. They had a bit of an earnings hit in the 3rd quarter, and he bought more. He has a $92 target on this.

Medtronic Inc (MDT-N)
April 19, 2017

(A Top Pick May 13/16. Up 2%.) The leading medical device company. He owns it because they have a plethora of products right across the range. They had a bit of an earnings hit in the 3rd quarter, and he bought more. He has a $92 target on this.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$80.320
Owned
Yes
DON'T BUY
DON'T BUY
April 6, 2017

There has been some major earnings volatility around this one recently. So he has backed off. They have a mid- to high- single digit earnings growth rate, but you are paying twice that. The PE to growth rate is too high. You are paying top dollar for the growth you are getting.

Medtronic Inc (MDT-N)
April 6, 2017

There has been some major earnings volatility around this one recently. So he has backed off. They have a mid- to high- single digit earnings growth rate, but you are paying twice that. The PE to growth rate is too high. You are paying top dollar for the growth you are getting.

Cameron Hurst
Chief Investment Officer, Equium Capital Management
Price
$80.220
Owned
Unknown
COMMENT
COMMENT
February 22, 2017

This has everything you can think of that is tools related, from your head all the way down to your toes; cardiovascular, stent. The dominant player in medical technologies. Trading at 17X next year’s earnings. Had a hiccup last quarter, but all they had to do was show that things were back on track. He likes this.

Medtronic Inc (MDT-N)
February 22, 2017

This has everything you can think of that is tools related, from your head all the way down to your toes; cardiovascular, stent. The dominant player in medical technologies. Trading at 17X next year’s earnings. Had a hiccup last quarter, but all they had to do was show that things were back on track. He likes this.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$79.620
Owned
Yes
PAST TOP PICK
PAST TOP PICK
January 25, 2017

(A Top Pick Oct 11/16. Down 9.87%.) For the most part of 2016, there was a rotation out of Pharma and into medical devices. Great company, well-established and a good yield.

Medtronic Inc (MDT-N)
January 25, 2017

(A Top Pick Oct 11/16. Down 9.87%.) For the most part of 2016, there was a rotation out of Pharma and into medical devices. Great company, well-established and a good yield.

Dean Orrico
President, Middlefield Capital Corp.
Price
$74.490
Owned
Yes
COMMENT
COMMENT
October 17, 2016

He likes healthcare “devices”, because it is the area that is least likely to be attacked by a government. They are somewhat less regulated from a price standpoint. This company has very strong market share in rhythm devices. Earnings for the year should be up about 7% over last year, but should accelerate up to about 11% next year. It has consolidated between $80 and $90 going back to June. Sitting at around the 150 day moving average, so technically is in a good spot. You should see earnings accelerate going forward, which is what he cares about.

Medtronic Inc (MDT-N)
October 17, 2016

He likes healthcare “devices”, because it is the area that is least likely to be attacked by a government. They are somewhat less regulated from a price standpoint. This company has very strong market share in rhythm devices. Earnings for the year should be up about 7% over last year, but should accelerate up to about 11% next year. It has consolidated between $80 and $90 going back to June. Sitting at around the 150 day moving average, so technically is in a good spot. You should see earnings accelerate going forward, which is what he cares about.

David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$82.570
Owned
Unknown
DON'T BUY
DON'T BUY
October 14, 2016

Seasonally, this doesn’t do too well at this time of year. That is pretty common for all the healthcare instrument stocks in general. Technically it is developing a downward trend and recently broke 2 support levels.

Medtronic Inc (MDT-N)
October 14, 2016

Seasonally, this doesn’t do too well at this time of year. That is pretty common for all the healthcare instrument stocks in general. Technically it is developing a downward trend and recently broke 2 support levels.

Don Vialoux
Research Analyst, TimingTheMarket.CA & EquityClock.COM
Price
$82.710
Owned
Unknown
TOP PICK
TOP PICK
October 11, 2016

A medical device business, one of the largest in the world. A very diverse product line. Valuation at about 18X earnings, the high end of the range, but medical devices are trading at a premium to Pharma. He sees single digit revenue growth and double digit earnings growth, and expects some real growth to come out of things like aortic valve replacement. Dividend yield of 2.07%.

Medtronic Inc (MDT-N)
October 11, 2016

A medical device business, one of the largest in the world. A very diverse product line. Valuation at about 18X earnings, the high end of the range, but medical devices are trading at a premium to Pharma. He sees single digit revenue growth and double digit earnings growth, and expects some real growth to come out of things like aortic valve replacement. Dividend yield of 2.07%.

Dean Orrico
President, Middlefield Capital Corp.
Price
$83.200
Owned
Yes
HOLD
HOLD
October 4, 2016

Has a target price of $98, so there is decent upside to it. They are talking about launching a robotic surgery system, so that is something to keep an eye on. It is not at the top of his list, so he wouldn’t be adding to it here.

Medtronic Inc (MDT-N)
October 4, 2016

Has a target price of $98, so there is decent upside to it. They are talking about launching a robotic surgery system, so that is something to keep an eye on. It is not at the top of his list, so he wouldn’t be adding to it here.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$86.110
Owned
Yes
TOP PICK
TOP PICK
September 23, 2016

In general he has been cautious on Biotechs, but this is a medical devices company. It is very, very solid. In the next 5 years it should be growing revenues at mid-single digits. Earnings at low double digits. Dividend yield of 1.96%.

Medtronic Inc (MDT-N)
September 23, 2016

In general he has been cautious on Biotechs, but this is a medical devices company. It is very, very solid. In the next 5 years it should be growing revenues at mid-single digits. Earnings at low double digits. Dividend yield of 1.96%.

John Stephenson
President & CEO, Stephenson & Company Capital Management
Price
$87.710
Owned
Yes
COMMENT
COMMENT
September 1, 2016

The medical device companies have done a lot better this year, versus pharmaceutical companies. If you are buying shares of a healthcare company right now, he would buy a pharmaceutical name or his Top Pick at the end. (See Top Picks.)

Medtronic Inc (MDT-N)
September 1, 2016

The medical device companies have done a lot better this year, versus pharmaceutical companies. If you are buying shares of a healthcare company right now, he would buy a pharmaceutical name or his Top Pick at the end. (See Top Picks.)

Barry Schwartz
CIO & Portfolio Manager, Baskin Wealth Management
Price
$86.980
Owned
Unknown
TOP PICK
TOP PICK
August 30, 2016

A healthcare company, but not a pharmaceutical company. They are very big in cardiovascular and diabetes. Growing their top line at roughly 5%-10% per annum, and the bottom line closer to 12%-13% for the foreseeable future for the next 4-5 years. They are in the right place at the right time, and are likely to return about $1 billion a year to the shareholders for the next few years. They are committed to increasing their dividends. Dividend yield of 1.98%.

Medtronic Inc (MDT-N)
August 30, 2016

A healthcare company, but not a pharmaceutical company. They are very big in cardiovascular and diabetes. Growing their top line at roughly 5%-10% per annum, and the bottom line closer to 12%-13% for the foreseeable future for the next 4-5 years. They are in the right place at the right time, and are likely to return about $1 billion a year to the shareholders for the next few years. They are committed to increasing their dividends. Dividend yield of 1.98%.

John Stephenson
President & CEO, Stephenson & Company Capital Management
Price
$86.850
Owned
Yes
PAST TOP PICK
PAST TOP PICK
July 13, 2016

(Top Pick May 13/16, Down 9%) They gave positive guidance last earnings report. Healthcare stocks are starting to work over the last two to three weeks.

Medtronic Inc (MDT-N)
July 13, 2016

(Top Pick May 13/16, Down 9%) They gave positive guidance last earnings report. Healthcare stocks are starting to work over the last two to three weeks.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$88.750
Owned
Yes
HOLD
HOLD
July 7, 2016

Was a darling in the sector. She views it as a steady eddy right now. It is an acceptable hold if you are diversifying your healthcare holdings. She likes the company as a long term hold of 5 years.

Was a darling in the sector. She views it as a steady eddy right now. It is an acceptable hold if you are diversifying your healthcare holdings. She likes the company as a long term hold of 5 years.

Liz Miller
President, Summit Place Financial Advisors
Price
$87.490
Owned
Unknown
HOLD
HOLD
June 22, 2016

Acquired Covidien about a year or so ago. A very synergistic acquisition. Has had a great run. A name he would absolutely continue to hold onto. Great balance sheet. Growing in their businesses. His preferred choice in medical devices.

Medtronic Inc (MDT-N)
June 22, 2016

Acquired Covidien about a year or so ago. A very synergistic acquisition. Has had a great run. A name he would absolutely continue to hold onto. Great balance sheet. Growing in their businesses. His preferred choice in medical devices.

Paul MacDonald
Chief Investment Officer & Portfolio Manager, Harvest Portfolios Group
Price
$84.260
Owned
Yes
PAST TOP PICK
PAST TOP PICK
June 21, 2016

(A Top Pick Sept 18/15. Up 22.15%.) Their merger with Covidien has worked out well, and they successfully moved their headquarters to Ireland. There continues to be hefty chunks of cash flow that can be used for tuck in acquisitions or further dividend increases down the road.

Medtronic Inc (MDT-N)
June 21, 2016

(A Top Pick Sept 18/15. Up 22.15%.) Their merger with Covidien has worked out well, and they successfully moved their headquarters to Ireland. There continues to be hefty chunks of cash flow that can be used for tuck in acquisitions or further dividend increases down the road.

Mohsin Bashir
VP Investments, Stone Asset Management
Price
$84.590
Owned
Yes
COMMENT
COMMENT
June 14, 2016

He likes healthcare, and specifically medical devices. This company is big on implants, both for heart and minimally invasive, as well spinal implants. With an aging population, a lot of replacement parts are required, and this company is doing a great job. 1.8% dividend yield. He likes the stock.

Medtronic Inc (MDT-N)
June 14, 2016

He likes healthcare, and specifically medical devices. This company is big on implants, both for heart and minimally invasive, as well spinal implants. With an aging population, a lot of replacement parts are required, and this company is doing a great job. 1.8% dividend yield. He likes the stock.

David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$85.490
Owned
Yes
BUY
BUY
June 13, 2016

For 5-10 years? A good name. Basically medical devices. A very, very strong company. Well-managed. Good pipeline of products.

Medtronic Inc (MDT-N)
June 13, 2016

For 5-10 years? A good name. Basically medical devices. A very, very strong company. Well-managed. Good pipeline of products.

John Stephenson
President & CEO, Stephenson & Company Capital Management
Price
$85.700
Owned
Yes
COMMENT
COMMENT
June 7, 2016

Have been very heavily into pacemakers and are getting very heavily into spinal treatments. Just made an acquisition of a small company that helps out in spinal surgeries. This has been a wonderful performer over time. Free cash flow growth has been in the 13% range over the last 5 years. Dividend has been growing at roughly 9%. A nice steady stock.

Have been very heavily into pacemakers and are getting very heavily into spinal treatments. Just made an acquisition of a small company that helps out in spinal surgeries. This has been a wonderful performer over time. Free cash flow growth has been in the 13% range over the last 5 years. Dividend has been growing at roughly 9%. A nice steady stock.

David Driscoll
President & CEO, Liberty International Investment Management Inc
Price
$83.720
Owned
Unknown
BUY
BUY
June 1, 2016

He is always very picky when it comes to medical equipment supply companies. This has been one of the major players for very long time, and is one of the better performers. You have the aging and the baby boomers. Some of the healthcare stocks have been beaten and dragged down with the Biotechs. Biotechs started to break out yesterday, which will pull up all health related companies. This has some good fundamentals.

He is always very picky when it comes to medical equipment supply companies. This has been one of the major players for very long time, and is one of the better performers. You have the aging and the baby boomers. Some of the healthcare stocks have been beaten and dragged down with the Biotechs. Biotechs started to break out yesterday, which will pull up all health related companies. This has some good fundamentals.

Matthew McCall
President, Penn Financial Group
Price
$80.520
Owned
Unknown
TOP PICK
TOP PICK
May 25, 2016

Cardiac implants, spinal implants and diabetes devices. A play on the secular theme of spending on healthcare. They are all about scale. It is fundamentally very attractive. They have a dominant role and can save the system money with their implants.

Cardiac implants, spinal implants and diabetes devices. A play on the secular theme of spending on healthcare. They are all about scale. It is fundamentally very attractive. They have a dominant role and can save the system money with their implants.

David Burrows
President & Chief Investment Strategist, Barometer Capital Management
Price
$81.080
Owned
Yes
TOP PICK
TOP PICK
May 13, 2016

Medical implants. A play on the aging population. About 1.5 years ago, they took out the old Tyco division called Covidien, their healthcare business. Covidien had got to Ireland, and this company now has done the inversion. This company is now sitting on boatloads of cash globally. We are going to see higher dividends, share buybacks and probably more acquisitions. Target price of $88.

Medical implants. A play on the aging population. About 1.5 years ago, they took out the old Tyco division called Covidien, their healthcare business. Covidien had got to Ireland, and this company now has done the inversion. This company is now sitting on boatloads of cash globally. We are going to see higher dividends, share buybacks and probably more acquisitions. Target price of $88.

Bruce Murray
CEO & Chief Investment Officer, The Murray Wealth Group
Price
$80.710
Owned
Yes
COMMENT
COMMENT
October 1, 2015

60% of his assets are outside of Canada and he is comfortable with that. He looked at it and decided it was expensive. It is starting to come down.

Medtronic Inc (MDT-N)
October 1, 2015

60% of his assets are outside of Canada and he is comfortable with that. He looked at it and decided it was expensive. It is starting to come down.

Norman Levine
Managing Director, Portfolio Management Corp
Price
$68.400
Owned
No
TOP PICK
TOP PICK
September 18, 2015

(A Top Pick July 18/14. Up 14.85%.) Acquired Covidian at about $43 billion, and moved their headquarters to Dublin Ireland for lower taxes. The acquisition transforms them into the largest medical device company globally. It also gives them line of sight to be more significant in emerging markets, as well as general surgical tools. Dividend yield of 2.16%.

Medtronic Inc (MDT-N)
September 18, 2015

(A Top Pick July 18/14. Up 14.85%.) Acquired Covidian at about $43 billion, and moved their headquarters to Dublin Ireland for lower taxes. The acquisition transforms them into the largest medical device company globally. It also gives them line of sight to be more significant in emerging markets, as well as general surgical tools. Dividend yield of 2.16%.

Mohsin Bashir
VP Investments, Stone Asset Management
Price
$70.330
Owned
Yes
COMMENT
COMMENT
August 13, 2015

This is the one part of the health market that has seen pressure on the pricing side. As hospitals get together and form bigger consortiums, they are able to exert a bit of pressure. When people look at the margins in this area, they feel that maybe they don’t have to be so high. For some of their products, if it is differentiated enough, you could have a little bit of pricing, but there is quite a bit of product of that can be replaced by generics and this is what is happening. She would like to see this start improving and reversing before she got constructive on the name.

Medtronic Inc (MDT-N)
August 13, 2015

This is the one part of the health market that has seen pressure on the pricing side. As hospitals get together and form bigger consortiums, they are able to exert a bit of pressure. When people look at the margins in this area, they feel that maybe they don’t have to be so high. For some of their products, if it is differentiated enough, you could have a little bit of pricing, but there is quite a bit of product of that can be replaced by generics and this is what is happening. She would like to see this start improving and reversing before she got constructive on the name.

Jennifer Radman
VP & Sr. Portfolio Manager, Caldwell Investment Management
Price
$77.480
Owned
No
PARTIAL SELL
PARTIAL SELL
May 7, 2015

This has been doing tremendously well. They do have a lot of debt, and their debt load is a little bit scary for him. If he owned this, he would be thinking of paring back or selling. We are also moving into that time of the year when stocks do not do that well.

This has been doing tremendously well. They do have a lot of debt, and their debt load is a little bit scary for him. If he owned this, he would be thinking of paring back or selling. We are also moving into that time of the year when stocks do not do that well.

Benj Gallander
President, Contra the Heard Investment Letter
Price
$74.600
Owned
No
BUY
BUY
January 8, 2015

$80.49 model price, 10% upside. He is positive on it and would buy it here.

Medtronic Inc (MDT-N)
January 8, 2015

$80.49 model price, 10% upside. He is positive on it and would buy it here.

Brian Acker, CA
Chief Executive Officer, President and Chief Inves, Acker Finley Inc.
Price
$74.750
Owned
Unknown
BUY WEAKNESS
BUY WEAKNESS
December 9, 2014

Likes the space they are in. It is knees and spines, which plays into the aging demographic’ profile, and as the US and other economies improve, that will be directed into some of these areas as a somewhat discretionary spend. Prefers Johnson & Johnson (JNJ-N) which has the medical devices division. If their acquisition goes through, it will be a positive. She would wait for it to pull back a little.

Medtronic Inc (MDT-N)
December 9, 2014

Likes the space they are in. It is knees and spines, which plays into the aging demographic’ profile, and as the US and other economies improve, that will be directed into some of these areas as a somewhat discretionary spend. Prefers Johnson & Johnson (JNJ-N) which has the medical devices division. If their acquisition goes through, it will be a positive. She would wait for it to pull back a little.

Christine Poole
CEO & Managing Director, GlobeInvest Capital Management
Price
$74.720
Owned
No
COMMENT
COMMENT
August 5, 2014

(Market Call Minute.) Loves the health care in the US. He is playing this through C. R. Bard (BCR-N) and Zimmer (ZMH-N).

Medtronic Inc (MDT-N)
August 5, 2014

(Market Call Minute.) Loves the health care in the US. He is playing this through C. R. Bard (BCR-N) and Zimmer (ZMH-N).

Barry Schwartz
CIO & Portfolio Manager, Baskin Wealth Management
Price
$61.990
Owned
No
COMMENT
COMMENT
July 25, 2014

Used to be a dividend aristocrat in that it paid an increasing dividend every single year, for a long period of time. Good balance sheet, leveraged to the tool market in the medical space. Somewhat slower growth during the recession. They are acquiring Covidien (COV-N) and will re-base in Ireland giving them lower taxes. This will accelerate their growth. Longer-term, if you buy the story, you’ll be okay, but it is a multi-year story. A slow growth story.

Medtronic Inc (MDT-N)
July 25, 2014

Used to be a dividend aristocrat in that it paid an increasing dividend every single year, for a long period of time. Good balance sheet, leveraged to the tool market in the medical space. Somewhat slower growth during the recession. They are acquiring Covidien (COV-N) and will re-base in Ireland giving them lower taxes. This will accelerate their growth. Longer-term, if you buy the story, you’ll be okay, but it is a multi-year story. A slow growth story.

Darren Sissons
Vice President and Partner, Campbell Lee & Ross
Price
$62.900
Owned
Unknown
TOP PICK
TOP PICK
July 18, 2014

On the cusp of a transformational acquisition, the $43 billion purchase of Covidian (COV-N). This changes their headquarters with a tax inversion deal, making Covidian a 30% owner of the new Medtronic. In order for a tax inversion to take place, you have to own at least 20%, so maybe the extra buffer of 30% will appease regulators, and keep everybody happy. This would allow them to have foreign profit, somewhere in the realm of about $14 billion, and be able to re-disperse them among their existing shareholders. A good line of sight for a growing dividend, further share buybacks, as well as future tuck in acquisitions. This deal would make them the biggest and most diversified medical devices company globally. Also, developing a series of new products. Yield of 1.97%.

Medtronic Inc (MDT-N)
July 18, 2014

On the cusp of a transformational acquisition, the $43 billion purchase of Covidian (COV-N). This changes their headquarters with a tax inversion deal, making Covidian a 30% owner of the new Medtronic. In order for a tax inversion to take place, you have to own at least 20%, so maybe the extra buffer of 30% will appease regulators, and keep everybody happy. This would allow them to have foreign profit, somewhere in the realm of about $14 billion, and be able to re-disperse them among their existing shareholders. A good line of sight for a growing dividend, further share buybacks, as well as future tuck in acquisitions. This deal would make them the biggest and most diversified medical devices company globally. Also, developing a series of new products. Yield of 1.97%.

Mohsin Bashir
VP Investments, Stone Asset Management
Price
$62.360
Owned
Yes
BUY
BUY
February 7, 2014

Is this a good time to get into health care stocks and what would you recommend? Likes Abbott Labs (ABT-N) very much. Spun off their pharmaceutical R&D business about 2 years ago and split themselves up into 4 different divisions. If looking at global healthcare companies, you can’t go wrong with something like Johnson & Johnson (JNJ-N). Products are cheap and they can easily raise costs. Also likes Medtronics (MDT-N) which is a device manufacturer.

Medtronic Inc (MDT-N)
February 7, 2014

Is this a good time to get into health care stocks and what would you recommend? Likes Abbott Labs (ABT-N) very much. Spun off their pharmaceutical R&D business about 2 years ago and split themselves up into 4 different divisions. If looking at global healthcare companies, you can’t go wrong with something like Johnson & Johnson (JNJ-N). Products are cheap and they can easily raise costs. Also likes Medtronics (MDT-N) which is a device manufacturer.

Michael Bowman
Portfolio Manager, Wickham Investment Management
Price
$55.590
Owned
Unknown
COMMENT
COMMENT
August 21, 2013

Likes the company and if you are comfortable with this, he thinks the medical device space is very positive demographically. You could hold this for the longer-term.

Medtronic Inc (MDT-N)
August 21, 2013

Likes the company and if you are comfortable with this, he thinks the medical device space is very positive demographically. You could hold this for the longer-term.